Kalaris Therapeutics (KLRS) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Kalaris Therapeutics (NASDAQ: KLRS):

  • 11/16/2026 – Kalaris Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/8/2026 – Kalaris Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
  • 11/4/2026 – Kalaris Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 10/31/2026 – Kalaris Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 10/22/2026 – Kalaris Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 9/24/2026 – Kalaris Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Kalaris Therapeutics Stock Performance

Kalaris Therapeutics stock traded down $0.04 during trading hours on Friday, reaching $1.31. 26,332 shares of the stock were exchanged, compared to its average volume of 127,700. The stock has a market cap of $31.31 million, a P/E ratio of -0.71 and a beta of 0.47. Kalaris Therapeutics Inc. has a 52-week low of $1.30 and a 52-week high of $11.88. The firm’s 50 day moving average is $2.37 and its 200 day moving average is $4.91.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06. Equities research analysts expect that Kalaris Therapeutics Inc. will post -1.92 EPS for the current fiscal year.

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.

Read More

Receive News & Ratings for Kalaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.